MCID: PRM126
MIFTS: 53

Primary Peritoneal Carcinoma malady

Cancer diseases, Rare diseases categories

Summaries for Primary Peritoneal Carcinoma

About this section


Wikipedia:63 Primary peritoneal cancer or carcinoma is also known as: serous surface papillary carcinoma, primary... more...

MalaCards based summary: Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to peritoneal carcinoma and papillary carcinoma, and has symptoms including weight loss, nausea and vomiting and constipation. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (breast cancer 1, early onset), and among its related pathways are Homologous Recombination Repair and DNA Damage Induced 14-3-3Sigma Signaling. The compounds topotecan and vinorelbine have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and eye, and related mouse phenotypes are liver/biliary system and renal/urinary system.

Aliases & Classifications for Primary Peritoneal Carcinoma

About this section
Sources:
47Orphanet, 60UMLS, 26ICD10 via Orphanet
See all sources

Primary Peritoneal Carcinoma, Aliases & Descriptions:

Name: Primary Peritoneal Carcinoma 47 60
Serous Surface Papillary Carcinoma 47 60
Extra-Ovarian Primary Peritoneal Carcinoma 47
Primary Peritoneal Serous Adenocarcinoma 60
 
Primary Peritoneal Serous Carcinoma 47
Eoppc 47
Ppc 47


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases, Rare diseases
Orphanet: 47 
Rare tumors


Characteristics (Orphanet epidemiological data):

47
serous surface papillary carcinoma:
Age of onset: Adult; Age of death: normal life expectancy


External Ids:

Orphanet47 168829
ICD10 via Orphanet26 C48.2

Related Diseases for Primary Peritoneal Carcinoma

About this section

Diseases in the Peritoneal Carcinoma family:

Peritoneal Benign Neoplasm primary peritoneal carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 125)
idRelated DiseaseScoreTop Affiliating Genes
1peritoneal carcinoma32.3BRCA2, BRCA1
2papillary carcinoma30.8RET, ERBB2, MUC16, PGR, BRCA2
3tuberculosis30.5IFNG, CXCL10, IL10
4endometriosis30.3PGR, IL8, MUC16
5adenocarcinoma29.1ERBB2, EGFR, CEACAM5, CXCL10, MUC16, PGR
6peritonitis11.1
7struma ovarii10.5MUC16
8adenofibroma10.5MUC16
9hereditary breast ovarian cancer10.5BRCA2
10ovarian serous cystadenocarcinoma10.5MUC16
11papillary serous adenocarcinoma10.5
12pleurisy10.5MUC16
13cystadenoma10.5BRCA1
14uterine fibroid10.5PGR
15cystadenocarcinoma10.5MUC16, CEACAM5
16papillary adenocarcinoma10.4MUC16, CEACAM5
17brca1 and brca2 hereditary breast and ovarian cancer10.4BRCA1, BRCA2
18endodermal sinus tumor10.4CEACAM5, MUC16
19fallopian tube cancer10.4BRCA1, BRCA2
20breast cancer10.4BRCA1, BRCA2
21neuroblastoma10.4TP53
22ovarian cystadenoma10.4MUC16, BRCA1
23lynch syndrome10.4BRCA1, BRCA2
24paracoccidioidomycosis10.4IL10, CXCL10
25meningitis10.3IL8, CXCL10
26dysgerminoma10.3BRCA2, BRCA1
27sex cord-gonadal stromal tumor10.3PGR, CEACAM5
28autosomal dominant disease10.3RET, BRCA1
29viral meningitis10.3CXCL10, IL8
30mammary paget's disease10.3ERBB2, PGR
31ovary papillary carcinoma10.3
32breast disease10.3PGR, ERBB2
33bronchiolitis obliterans10.3CXCL10, IL8
34hepatitis10.3
35ovarian serous carcinoma10.3
36in situ carcinoma10.3
37syphilis10.3
38tertiary syphilis10.3
39cervical adenocarcinoma10.3CEACAM5, MUC16, PGR
40folliculitis10.3EGFR
41cowden disease10.3BRCA2, BRCA1, RET
42bilateral breast cancer10.2PGR, BRCA2, BRCA1
43gynecomastia10.2PGR, BRCA2, BRCA1
44gallbladder cancer10.2CEACAM5, TP53
45alcoholic hepatitis10.2IL10, IL8
46tubular adenocarcinoma10.2PGR, CEACAM5, ERBB2
47gastric adenocarcinoma10.2ERBB2, MUC16, CEACAM5
48giant cell glioblastoma10.2EGFR
49tuberculoid leprosy10.2IFNG, IL10
50xeroderma pigmentosum, variant type10.2ERCC1, BRCA1, TP53

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to primary peritoneal carcinoma

Symptoms for Primary Peritoneal Carcinoma

About this section

Symptoms:

 47 (show all 9)
  • anomalies of the abdominal wall
  • nausea/vomiting/regurgitation/merycism/hyperemesis
  • acute abdominal pain/colic
  • constipation
  • peritoneal diseases
  • neoplasms/tumors
  • ovary/fallopian tube neoplasm/tumor/carcinoma/cancer (excl. teratoma/germinoma)
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • early death/lethality

HPO human phenotypes related to Primary Peritoneal Carcinoma:

(show all 7)
id Description Frequency HPO Source Accession
1 weight loss hallmark (90%) HP:0001824
2 nausea and vomiting hallmark (90%) HP:0002017
3 constipation hallmark (90%) HP:0002019
4 abdominal pain hallmark (90%) HP:0002027
5 abnormality of the peritoneum hallmark (90%) HP:0002585
6 abnormality of the abdominal wall hallmark (90%) HP:0004298
7 ovarian neoplasm hallmark (90%) HP:0100615

Drugs & Therapeutics for Primary Peritoneal Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Primary Peritoneal Carcinoma

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

About this section

Anatomical Context for Primary Peritoneal Carcinoma

About this section

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

31
Ovary, Brain, Eye, Lymph node, Breast, Testes, Endothelial

Animal Models for Primary Peritoneal Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

35 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.7EGFR, ERCC1, IL10, IFNG, TP53
2MP:00053678.5TP53, BRCA1, RET, IFNG, ERCC1, EGFR
3MP:00053828.3TP53, IFNG, IL10, ERBB2, EGFR
4MP:00053718.3TP53, BRCA2, BRCA1, PGR, RET, IL10
5MP:00053888.3TP53, BRCA1, RET, IFNG, IL10, ERBB2
6MP:00030128.3TP53, PGR, RET, IFNG, IL10, EGFR
7MP:00053818.1TP53, BRCA2, BRCA1, RET, IFNG, IL10
8MP:00053697.9TP53, BRCA1, PGR, RET, IFNG, IL10
9MP:00053867.9TP53, BRCA2, BRCA1, PGR, RET, IFNG
10MP:00053907.9TP53, BRCA2, BRCA1, PGR, IFNG, IL10
11MP:00107717.9TP53, BRCA2, BRCA1, PGR, IFNG, IL10
12MP:00028737.9TP53, BRCA2, BRCA1, PGR, RET, IFNG
13MP:00053857.8TP53, BRCA1, PGR, CXCL10, RET, IFNG
14MP:00036317.8TP53, BRCA2, BRCA1, CXCL10, RET, IFNG
15MP:00020067.7EGFR, TP53, BRCA2, BRCA1, PGR, RET
16MP:00053797.7TP53, BRCA2, BRCA1, PGR, RET, IFNG
17MP:00053807.7PGR, BRCA1, BRCA2, TP53, RET, IFNG
18MP:00053787.7TP53, BRCA2, BRCA1, RET, IFNG, IL10
19MP:00053897.7PGR, BRCA1, BRCA2, TP53, RET, IFNG
20MP:00053847.4PGR, BRCA1, BRCA2, TP53, CXCL10, RET
21MP:00053977.4PGR, BRCA1, BRCA2, TP53, CXCL10, RET
22MP:00053877.4TP53, BRCA2, BRCA1, PGR, CXCL10, RET
23MP:00053767.4TP53, BRCA2, BRCA1, PGR, CXCL10, RET
24MP:00107687.3TP53, BRCA2, BRCA1, PGR, CXCL10, RET

Publications for Primary Peritoneal Carcinoma

About this section

Articles related to Primary Peritoneal Carcinoma:

(show top 50)    (show all 108)
idTitleAuthorsYear
1
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. (25056850)
2014
2
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. (24709487)
2014
3
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. (25016924)
2014
4
Solitary primary peritoneal carcinoma arising from the omentum. (25017281)
2014
5
Primary peritoneal carcinoma: regional cancer institute experience. (25419074)
2014
6
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). (24903764)
2014
7
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. (24798935)
2014
8
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. (24073344)
2013
9
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. (23791702)
2013
10
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. (23146339)
2013
11
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22710075)
2012
12
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22446624)
2012
13
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. (22037316)
2012
14
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. (22439406)
2012
15
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22943879)
2012
16
Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. (22348438)
2012
17
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (22772063)
2012
18
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. (22047770)
2012
19
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22155262)
2012
20
Primary peritoneal carcinoma in complete remission: a case report. (22199305)
2011
21
Peritoneal tuberculosis: a retrospective review of 20 cases and comparison with primary peritoneal carcinoma. (20973271)
2010
22
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. (20846715)
2010
23
The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. (21045830)
2010
24
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. (19162309)
2009
25
RET/PTC rearrangement occurring in primary peritoneal carcinoma. (19147513)
2009
26
Primary peritoneal carcinoma in a young woman with suspected endometriosis. (19327764)
2009
27
Primary peritoneal carcinoma: computed tomography and magnetic resonance findings. (18664839)
2008
28
Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. (18543395)
2008
29
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. (17257661)
2007
30
Colorectal resection in patients with ovarian and primary peritoneal carcinoma. (16730631)
2006
31
Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. (16515579)
2006
32
Primary peritoneal carcinoma: a rare neoplasm with pleomorphic trophoblastic morphology. (16907865)
2006
33
Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. (16769104)
2006
34
Asymptomatic primary peritoneal carcinoma presenting as adenocarcinoma on routine cervical cytology. (16553187)
2006
35
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. (16564077)
2006
36
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. (15589582)
2005
37
Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer? (15607552)
2005
38
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. (14615451)
2003
39
Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma. (12592068)
2002
40
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution. (11371148)
2001
41
Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. (10738268)
2000
42
Solitary brain metastasis indicating recurrent primary peritoneal carcinoma. (10912420)
1999
43
Importance of lymph node metastases in primary peritoneal carcinoma. (9701204)
1998
44
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. (9692840)
1998
45
Extraovarian primary peritoneal carcinoma. (9644683)
1998
46
Prognostic factors in extraovarian primary peritoneal carcinoma. (9826465)
1998
47
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. (9367697)
1997
48
Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. (8602811)
1996
49
Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. (8690292)
1996
50
Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. (8467455)
1993

Variations for Primary Peritoneal Carcinoma

About this section

Expression for genes affiliated with Primary Peritoneal Carcinoma

About this section
Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for genes affiliated with Primary Peritoneal Carcinoma

About this section

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 53)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0BRCA1, BRCA2
29.8BRCA1, TP53
39.8BRCA1, TP53
49.8IL10, IFNG
59.7ERCC1, BRCA1, BRCA2
6
Show member pathways
9.7BRCA2, BRCA1, ERCC1
79.7EGFR, IL8
89.6RET, IL10, IL8
99.5BRCA1, IFNG, IL8
10
Show member pathways
9.5BRCA1, BRCA2, TP53
119.5TP53, BRCA2, BRCA1
12
Show member pathways
Transcription NF kB signaling pathway58
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response58
9.5IL8, IFNG, CXCL10
13
Show member pathways
Development ERBB family signaling58
Development GDNF family signaling58
9.5RET, ERBB2, EGFR
149.5RET, ERBB2, EGFR
159.4IL8, IL10, IFNG
169.4IFNG, IL10, IL8
179.4IFNG, IL10, IL8
189.4IFNG, ERBB2, EGFR
199.3EGFR, ERBB2, TP53
20
Show member pathways
9.3TP53, ERBB2, EGFR
21
Show member pathways
Signal transduction PTEN pathway58
9.3EGFR, ERBB2, TP53
229.3TP53, ERBB2, EGFR
23
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.3EGFR, ERBB2, TP53
24
Show member pathways
9.3TP53, ERBB2, EGFR
259.3IL8, IFNG, TP53
269.3IL8, IFNG, TP53
27
Show member pathways
Immune response MIF in innate immunity response58
9.3IL8, IFNG, TP53
28
Show member pathways
9.3ERCC1, BRCA1, BRCA2, TP53
29
Show member pathways
9.3ERCC1, BRCA1, BRCA2, TP53
309.3EGFR, IL8, TP53
31
Show member pathways
9.2TP53, IFNG, EGFR
329.2TP53, IFNG, EGFR
339.1TP53, BRCA2, BRCA1, EGFR
34
Show member pathways
9.1TP53, CXCL10, IFNG, IL8
35
Show member pathways
9.0EGFR, ERBB2, BRCA2, TP53
36
Show member pathways
8.9TP53, IFNG, ERBB2, EGFR
378.9TP53, MIR497, MIR195
38
Show member pathways
8.9EGFR, ERBB2, IL8, IL10, CXCL10
39
Show member pathways
8.8TP53, BRCA2, BRCA1, ERBB2, EGFR
408.8TP53, BRCA2, BRCA1, ERBB2, EGFR
41
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
8.7TP53, CXCL10, IFNG, IL10, IL8
428.7TP53, CXCL10, IFNG, IL8, EGFR
43
Show member pathways
Signaling Pathways in Glioblastoma36
8.5EGFR, ERBB2, IL8, BRCA1, BRCA2, TP53
448.5TP53, BRCA1, MIR195, ERBB2, EGFR
45
Show member pathways
8.5TP53, PGR, CXCL10, IL8, ERBB2, EGFR
468.4TP53, BRCA2, RET, IL8, ERBB2, EGFR
47
Show member pathways
8.4TP53, CXCL10, IL10, IL8, ERBB2, EGFR
48
Show member pathways
8.2TP53, BRCA1, CXCL10, IL10, IL8, ERBB2
49
Show member pathways
8.0TP53, BRCA1, IFNG, IL10, IL8, ERBB2
50
Show member pathways
8.0TP53, CXCL10, IFNG, IL10, IL8, ERBB2

Compounds for genes affiliated with Primary Peritoneal Carcinoma

About this section

Compounds related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 175)
idCompoundScoreTop Affiliating Genes
1topotecan43 1210.7EGFR, MUC16, BRCA1
2vinorelbine43 49 1211.7EGFR, ERCC1, ERBB2, BRCA1
3fluticasone propionate43 49 59 1212.5IFNG, IL8, CXCL10, PGR
4polyinosinic-polycytidylic acid439.5IL10, IFNG, CXCL10, IL8
5capecitabine43 49 1211.5EGFR, ERBB2, PGR
6il 10439.4CXCL10, IFNG, IL10, IL8
7tarc439.4IL8, IFNG, IL10, CXCL10
8taxane439.4EGFR, TP53, PGR, ERBB2
9ccl343 2810.4CXCL10, IFNG, IL10, IL8
10neopterin439.3IL8, IL10, CXCL10, IFNG
11resveratrol43 59 24 1212.3PGR, ERBB2, BRCA1, BRCA2, TP53
12hydrocortisone43 2 59 1212.2IL10, IFNG, ERBB2, IL8, CXCL10
13methotrexate49 43 1211.2IL10, PGR, ERBB2, BRCA2, BRCA1, ERCC1
14suberoylanilide hydroxamic acid439.2EGFR, ERBB2, IFNG, TP53
15bortezomib43 49 1211.2EGFR, BRCA1, ERBB2, TP53
16herbimycin a43 5910.1RET, IFNG, IL8, ERBB2, EGFR
174-hydroxytamoxifen439.0ERBB2, BRCA1, PGR, IFNG, BRCA2, EGFR
18melphalan43 49 1211.0ERCC1, TP53, MUC16, IFNG
19etoposide43 49 59 1212.0BRCA2, ERCC1, ERBB2, BRCA1, TP53
20gemcitabine43 49 1210.9IL10, ERBB2, TP53, ERCC1, EGFR, BRCA1
21thymidylate438.9TP53, BRCA1, IL10, ERBB2, ERCC1, EGFR
22tamoxifen43 49 28 1211.9BRCA2, BRCA1, PGR, ERBB2, EGFR, TP53
23leucovorin43 49 1210.8CEACAM5, EGFR, ERCC1, ERBB2, PGR
24docetaxel43 49 59 1211.7TP53, EGFR, BRCA2, BRCA1, PGR, ERCC1
25gold438.7CXCL10, BRCA2, CEACAM5, BRCA1, MUC16
26ly294002438.7ERBB2, IL8, RET, IL10, TP53, EGFR
27irinotecan43 49 1210.6ERCC1, ERBB2, EGFR, CEACAM5, TP53
28cyclophosphamide43 49 1210.6TP53, BRCA1, PGR, MUC16, ERCC1, IL10
29agar438.6ERBB2, CEACAM5, RET, PGR, EGFR, BRCA1
30mitomycin c438.6TP53, BRCA2, ERCC1, BRCA1, CEACAM5, IL10
31testosterone43 59 24 1211.5BRCA1, PGR, MUC16, ERBB2, EGFR, BRCA2
32adriamycin438.5ERBB2, CEACAM5, TP53, BRCA2, PGR, BRCA1
33sb 20358043 599.5IL8, EGFR, IFNG, TP53, IL10
34oxaliplatin43 49 1210.5BRCA1, TP53, CEACAM5, ERBB2, ERCC1, EGFR
35carboplatin43 49 1210.4ERBB2, ERCC1, BRCA1, EGFR, IFNG, MUC16
36dexamethasone43 49 28 1211.4CXCL10, IFNG, IL10, IL8, PGR, MUC16
37retinoic acid43 249.3BRCA2, PGR, CXCL10, RET, IFNG, EGFR
38genistein43 28 59 2 24 1213.2CXCL10, IL8, EGFR, ERBB2, IFNG, RET
39paclitaxel43 49 1210.2ERBB2, BRCA1, ERCC1, EGFR, MUC16, PGR
40phosphatidylinositol438.1ERBB2, CEACAM5, RET, CXCL10, BRCA1, BRCA2
41thymidine43 248.9BRCA1, IL10, ERCC1, IFNG, TP53, CEACAM5
42butyrate437.9TP53, RET, IFNG, IL8, CEACAM5
435fluorouracil437.8PGR, BRCA1, CEACAM5, EGFR, ERCC1, TP53
44cycloheximide437.7CXCL10, PGR, BRCA1, BRCA2, IL10, ERBB2
45doxorubicin43 49 129.6EGFR, ERBB2, CEACAM5, MUC16, PGR, BRCA1
46cisplatin43 49 59 1210.6BRCA2, BRCA1, MUC16, CEACAM5, ERBB2, ERCC1
47progesterone43 28 59 24 1211.4EGFR, ERBB2, TP53, BRCA2, BRCA1, PGR
48estrogen437.1EGFR, CEACAM5, TP53, BRCA2, BRCA1, ERCC1
49paraffin437.1TP53, BRCA1, PGR, MUC16, RET, CEACAM5
50vegf436.1EGFR, TP53, BRCA1, ERBB2, IL8, IL10

GO Terms for genes affiliated with Primary Peritoneal Carcinoma

About this section

Cellular components related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor complexGO:00432359.6EGFR, ERBB2, RET
2transcription factor TFIID complexGO:00056699.5TP53, ERCC1
3endosome membraneGO:00100089.4EGFR, ERBB2, RET
4nucleoplasmGO:00056549.0ERCC1, PGR, BRCA1, BRCA2, TP53
5basolateral plasma membraneGO:00163238.9CEACAM5, ERBB2, EGFR
6extracellular spaceGO:00056158.4EGFR, MUC16, CXCL10, IFNG, IL10, IL8

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of MHC class II biosynthetic processGO:004534810.1IFNG, IL10
2response to molecule of bacterial originGO:000223710.0IL10, IL8
3embryonic organ developmentGO:004856810.0ERCC1, TP53
4negative regulation of growth of symbiont in hostGO:004413010.0IFNG, IL10
5DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9BRCA1, BRCA2, TP53
6positive regulation of cell cycle arrestGO:00711589.9BRCA1, TP53
7cellular response to estradiol stimulusGO:00713929.9IL10, EGFR
8response to X-rayGO:00101659.9TP53, BRCA2, ERCC1
9response to gamma radiationGO:00103329.9TP53, BRCA2, CXCL10
10nucleotide-excision repairGO:00062899.8TP53, BRCA2, ERCC1
11peptidyl-tyrosine phosphorylationGO:00181089.8EGFR, ERBB2, RET
12cell agingGO:00075699.8BRCA2, TP53
13cellular response to lipopolysaccharideGO:00712229.7IL8, IL10, IFNG
14double-strand break repairGO:00063029.6ERCC1, BRCA1, BRCA2, TP53
15positive regulation of DNA repairGO:00457399.5EGFR, BRCA1
16protein import into nucleus, translocationGO:00000609.5IFNG, TP53
17cell surface receptor signaling pathwayGO:00071669.5EGFR, ERBB2, IFNG, CXCL10
18cell cycle arrestGO:00070509.4IL8, IFNG, TP53
19cell proliferationGO:00082839.3EGFR, ERCC1, ERBB2, TP53
20positive regulation of transcription, DNA-templatedGO:00458939.3TP53, BRCA2, BRCA1, RET, IL10
21signal transductionGO:00071659.0EGFR, ERBB2, IL8, RET, CXCL10, PGR
22positive regulation of transcription from RNA polymerase II promoterGO:00459448.8EGFR, IL10, IFNG, CXCL10, BRCA1, TP53
23negative regulation of apoptotic processGO:00430668.5TP53, CEACAM5, IL10, EGFR

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:00050069.9EGFR, ERBB2
2transmembrane receptor protein tyrosine kinase activityGO:00047149.7EGFR, ERBB2, RET
3receptor signaling protein tyrosine kinase activityGO:00047169.5ERBB2, EGFR
4protein tyrosine kinase activityGO:00047139.4EGFR, ERBB2, RET
5protein phosphatase bindingGO:00199039.3TP53, ERBB2, EGFR
6enzyme bindingGO:00198999.2TP53, BRCA1, PGR, EGFR
7identical protein bindingGO:00428028.5EGFR, ERBB2, CEACAM5, TP53
8protein bindingGO:00055157.1PGR, BRCA1, BRCA2, TP53, MUC16, CXCL10

Products for genes affiliated with Primary Peritoneal Carcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Primary Peritoneal Carcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet